JPMorgan downgraded Otonomy (NASDAQ: OTIC ) from Overweight to Neutral with a price ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst PT Change Downgrades

Piper Jaffray Downgrades Otonomy (OTIC) to NeutralAugust 30, 2017 11:23 AM Otonomy (OTIC) PT Lowered to $9 at Cowen Amid Otividex Failure; Dramatic And Fast Changes NeededAugust 30, 2017 10:44 AM UPDATE: Otonomy (OTIC) Plunges Over 77% After Phase 3 Trial of OTIVIDEX FailsAugust 30, 2017 7:33 AM Otonomy (OTIC) Says AVERTS-1 Phase 3 Trial for OTIVIDEX Missed Primary EndpointAugust 30, 2017 7:02 AM